Medicenna Therapeutics Corp
MDNA
Company Profile
Business description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Contact
2 Bloor Street West
Suite 903
TorontoONM4W 3E2
CANT: +1 416 964-5442
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
17
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.90 | 2.50 | -0.03% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,433.04 | 32.18 | 0.07% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,800.20 | 99.81 | 0.46% |
| Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
| NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
| S&P 500 | 6,488.57 | 7.07 | 0.11% |
| S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |